Berengere Gruson, Taieb Chouaki, Xavier Cazals, Olivier Lortholary, Claire Rivoisy, Marie-Elisabeth Bougnoux, Fanny Lanternier, Louis Bernard, Fabrice Chrétien, Grégory Jouvion, Agnès Lefort, Guillaume Desoubeaux, Marie Desnos-Ollivier, Hélène Chaussade, Service des Maladies infectieuses et tropicales [CHU Necker], CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service de neuroradiologie [Tours], Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Histopathologie humaine et Modèles animaux, Institut Pasteur [Paris] (IP), Maladies génétiques d'expression pédiatrique (U933), Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Trousseau [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), CHU Trousseau [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Unité de Parasitologie-Mycologie, Service de Microbiologie [Hôpital Necker-Enfants-Malades, Paris], Assistance Publique - Hôpitaux de Paris, Université Paris Cité (UPCité), Hôpital Beaujon [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Mycologie moléculaire - Molecular Mycology, Institut Pasteur [Paris] (IP)-Centre National de la Recherche Scientifique (CNRS), Centre National de Référence Mycoses Invasives et Antifongiques - National Reference Center Invasive Mycoses & Antifungals (CNRMA), CHU Amiens-Picardie, French Mycosis Study Group: The following investigators participated in data collection: Florence Ader, and Florence Persat (Centre Hospitalo-Universitaire, Lyon), Marlène Amara and Noémie Degunzburg (Centre Hospitalier, Versailles), Eric Bailly (Centre Hospitalo-Universitaire, Tours), Julie Bonhomme (Centre Hospitalo-Universitaire, Caen), Nathalie Bourgeois, Anne-Sophie Brunel, and Laurence Lachaud (Centre Hospitalo-Universitaire, Montpellier), Damier Bouhour (Centre Hospitalier, Bourg en Bresse), Laure Chaput and Frédéric Pene (Hôpital Cochin, Paris), Emmanuel Chatelus, Aurélien Guffroy, and Valérie Letscher-Bru (Centre Hospitalo-Universitaire, Strasbourg), Arnaud Fekkar (Hôpital de La Pitié-Salpêtrière, Paris), Eglantine Haustraetee and Renaud Verdon (Centre Hospitalo-Universitaire, Caen) Christophe Hennequin and Jean-Rémi Lavillegrand (Hôpital Saint-Antoine, Paris), Benoît Henry, Stéphane Jaureguiberry, and Véronique Morel (Hôpital de La Pitié-Salpêtrière, Paris), Julien Jaubert, Julie Mathieu-Streit, andML Xelot (Centre Hospitalo-Universitaire, Saint Denis de la Réunion), Yoann Zerbib (Centre Hospitalo-Universitaire, CHU Amiens)., Maladies génétiques d'expression pédiatrique [CHU Trousseau] (Inserm U933), UF de Génétique moléculaire [CHU Trousseau], Desnos-Ollivier, Marie, Centre Hospitalier Régional Universitaire de Tours (CHRU TOURS), Institut Pasteur [Paris], Physiopathologie des maladies génétiques d'expression pédiatrique (UMRS_933), Sorbonne Université (SU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université de Paris (UP), and Centre National de la Recherche Scientifique (CNRS)-Institut Pasteur [Paris]
Though candidiasis is the most frequent invasive fungal infection, Candida spp. central nervous system (CNS) infections are rare but severe. To further describe clinico-patho-radiological presentations of this entity, we report a retrospective study from January 2005 to December 2018 including patients aged ≥ 28 days with proven or probable CNS candidiasis in France. Twenty-four patients were included. Seventeen patients (70%) had CNS localization secondary to disseminated candidiasis (10 with hematologic malignancies [HM]; the seven other patients had infective endocarditis [IE]). Among patients with HM, seven previously had lumbar puncture for intrathecal chemotherapy, the three others had IE. Among patients with disseminated infection, magnetic resonance imaging (MRI) evidenced meningitis (17%), micro-abscesses (58%), or vascular complications (67%). Seven patients (30%) had isolated CNS involvement related to neurosurgery (n = 2), CARD9 deficiency (n = 2), intravenous drug use, diabetes mellitus, or no identified predisposing condition (n = 1 each). All evaluated patients with isolated CNS involvement had meningitis on cerebrospinal fluid (CSF) and intracranial hypertension. For the latter patients, MRI evidenced meningitis (71%) or abscesses (57%). Among all patients, cerebrospinal fluid (CSF) culture grew Candida spp. in 31% of cases. CSF βDGlucan or mannan Ag were positive in respectively 86% and 80% of cases. Mortality attributed to CNS candidiasis was 42%: 53% in case of disseminated infection (70% for HM) and 14% in case of localized infection. CNS candidiasis are isolated or occur during disseminated infection in patients with HM and lumbar puncture for intrathecal chemotherapy or during IE. Clinical, radiological finding and outcome highly vary according to CNS localized versus disseminated candidiasis. Lay Summary Candida is a yeast and is the most common cause of fungal infections worldwide. Candida central nervous system (CNS) infections are rare, severe, and poorly described. We report a retrospective study from January 2005 to December 2018 including patients aged ≥ 28 days with proven or probable CNS candidiasis in France. Twenty-four patients were included (14 men, median age 51 years). Seventeen patients had CNS localization secondary to disseminated candidiasis from blood to CNS (10 with hematologic malignancies [HM], the seven other patients had infective endocarditis [IE]). Seven patients had isolated CNS involvement related to neurosurgery (n = 2), CARD9 deficiency (n = 2), intravenous drug use (n = 1), diabetes mellitus (n = 1), or no identified risk factor (n = 1). During Candida CNS infections, brain lesions were meningitis abscesses or vascular complications. Cerebrospinal fluid (CSF) culture grew Candida spp. in 31% of cases. Forty-two percent of patients died from infection: 53% in case of disseminated infection (70% for HM) and 14% in case of localized infection.